Combination therapy with Arsenic trioxide for hematological malignancies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 504-510

  Takahashi, Shinichiro ^a  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Acute lymphoid leukemia; Acute myeloid leukemia; Arsenic trioxide; Chronic lymphoid leukemia; Chronic myeloid leukemia; Combination therapy; Multiple myeloma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; IMATINIB; MELPHALAN; NUCLEAR MATRIX PROTEIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TANESPIMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL TYPE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; OXIDATIVE STRESS; PROMYELOCYTIC LEUKEMIA; QT INTERVAL; RASH; SALVAGE THERAPY; SIDE EFFECT; TACHYCARDIA; VOMITING;

EID: 78649819510     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009060504     Document Type: Article

References (69)

1. Verstovsek, S.; Giles, F.; Quintas-Cardama, A.; Perez, N.; Ravandi-Kashani, F.; Beran, M.; Freireich, E.; Kantarjian, H. Arsenicderivatives in hematologic malignancies: a role beyond acute promyelocyticleukemia? Hematol. Oncol., 2006, 24(4), 181-188.
2. Waxman, S.; Anderson, K.C. History of the development of arsenicderivatives in cancer therapy. Oncologist, 2001, 6(Suppl 2), 3-10.
3. Antman, K.H. Introduction: the history of arsenic trioxide in cancertherapy. Oncologist, 2001, 6(Suppl 2), 1-2.
4. Shen, Z.X.; Chen, G.Q.; Ni, J.H.; Li, X.S.; Xiong, S.M.; Qiu, Q.Y.; Zhu, J.; Tang, W.; Sun, G.L.; Yang, K.Q.; Chen, Y.; Zhou, L.; Fang, Z.W.; Wang, Y.T.; Ma, J.; Zhang, P.; Zhang, T.D.; Chen, S.J.; Chen, Z.; Wang, Z.Y. Use of arsenic trioxide (As2O3) in thetreatment of acute promyelocytic leukemia (APL): II. Clinical efficacyand pharmacokinetics in relapsed patients. Blood, 1997, 89(9), 3354-3360.
5. Soignet, S.L.; Maslak, P.; Wang, Z.G.; Jhanwar, S.; Calleja, E.; Dardashti, L.J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D.A.; Pandolfi, P.P.; Warrell, R.P., Jr. Complete remission aftertreatment of acute promyelocytic leukemia with arsenic trioxide. N.Engl. J. Med., 1998, 339(19), 1341-1348.
6. Shen, Z.X.; Shi, Z.Z.; Fang, J.; Gu, B.W.; Li, J.M.; Zhu, Y.M.; Shi, J.Y.; Zheng, P.Z.; Yan, H.; Liu, Y.F.; Chen, Y.; Shen, Y.; Wu, W.; Tang, W.; Waxman, S.; De The, H.; Wang, Z.Y.; Chen, S.J.; Chen, Z. All-trans retinoic acid/As2O3 combination yields a high qualityremission and survival in newly diagnosed acute promyelocyticleukemia. Proc. Natl. Acad. Sci. USA, 2004, 101(15), 5328-5335.
7. Wang, G.; Li, W.; Cui, J.; Gao, S.; Yao, C.; Jiang, Z.; Song, Y.; Yuan, C.J.; Yang, Y.; Liu, Z.; Cai, L. An efficient therapeutic approachto patients with acute promyelocytic leukemia using a combinationof arsenic trioxide with low-dose all-trans retinoic acid.Hematol. Oncol., 2004, 22(2), 63-71.
8. Lowenberg, B.; Downing, J.R.; Burnett, A. Acute myeloid leukemia.N. Engl. J. Med., 1999, 341(14), 1051-1062.
9. Douer, D.; Tallman, M.S. Arsenic trioxide: new clinical experiencewith an old medication in hematologic malignancies. J. Clin.Oncol., 2005, 23(10), 2396-2410.
10. Soignet, S.L.; Frankel, S.R.; Douer, D.; Tallman, M.S.; Kantarjian, H.; Calleja, E.; Stone, R.M.; Kalaycio, M.; Scheinberg, D.A.; Steinherz, P.; Sievers, E.L.; Coutre, S.; Dahlberg, S.; Ellison, R.; Warrell, R.P., Jr. United States multicenter study of arsenic trioxide inrelapsed acute promyelocytic leukemia. J. Clin. Oncol., 2001, 19(18), 3852-3860.
11. Mathews, V.; George, B.; Chendamarai, E.; Lakshmi, K.M.; Desire, S.; Balasubramanian, P.; Viswabandya, A.; Thirugnanam, R.; Abraham, A.; Shaji, R.V.; Srivastava, A.; Chandy, M. Single-agentarsenic trioxide in the treatment of newly diagnosed acute promyelocyticleukemia: long-term follow-up data. J. Clin. Oncol., 2010, 28(24), 3866-3871.
12. Zhu, J.; Koken, M.H.; Quignon, F.; Chelbi-Alix, M.K.; Degos, L.; Wang, Z.Y.; Chen, Z.; de The, H. Arsenic-induced PML targetingonto nuclear bodies: implications for the treatment of acute promyelocyticleukemia. Proc. Natl. Acad. Sci. USA, 1997, 94(8), 3978-3983.
13. Shao, W.; Fanelli, M.; Ferrara, F.F.; Riccioni, R.; Rosenauer, A.; Davison, K.; Lamph, W.W.; Waxman, S.; Pelicci, P.G.; Lo Coco, F.; Avvisati, G.; Testa, U.; Peschle, C.; Gambacorti-Passerini, C.; Nervi, C.; Miller, W.H., Jr. Arsenic trioxide as an inducer of apoptosisand loss of PML/RAR alpha protein in acute promyelocyticleukemia cells. J. Natl. Cancer Inst., 1998, 90(2), 124-133.
14. Zhu, X.H.; Shen, Y.L.; Jing, Y.K.; Cai, X.; Jia, P.M.; Huang, Y.; Tang, W.; Shi, G.Y.; Sun, Y.P.; Dai, J.; Wang, Z.Y.; Chen, S.J.; Zhang, T.D.; Waxman, S.; Chen, Z.; Chen, G.Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenictrioxide at clinically achievable concentrations. J. Natl.Cancer Inst., 1999, 91(9), 772-778.
15. Rousselot, P.; Labaume, S.; Marolleau, J.P.; Larghero, J.; Noguera, M.H.; Brouet, J.C.; Fermand, J.P. Arsenic trioxide and melarsoprolinduce apoptosis in plasma cell lines and in plasma cells from myelomapatients. Cancer Res., 1999, 59(5), 1041-1048.
16. Munshi, N.C.; Tricot, G.; Desikan, R.; Badros, A.; Zangari, M.; Toor, A.; Morris, C.; Anaissie, E.; Barlogie, B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 2002, 16(9), 1835-1837.
17. Rousselot, P.; Larghero, J.; Arnulf, B.; Poupon, J.; Royer, B.; Tibi, A.; Madelaine-Chambrin, I.; Cimerman, P.; Chevret, S.; Hermine, O.; Dombret, H.; Claude Brouet, J.; Paul Fermand, J. A clinical and pharmacological study of arsenic trioxide in advanced multiplemyeloma patients. Leukemia, 2004, 18(9), 1518-1521.
18. Ravandi, F. Arsenic trioxide: expanding roles for an ancient drug?Leukemia, 2004, 18(9), 1457-1459.
19. List, A.; Beran, M.; DiPersio, J.; Slack, J.; Vey, N.; Rosenfeld, C.S.; Greenberg, P. Opportunities for Trisenox (arsenic trioxide) inthe treatment of myelodysplastic syndromes. Leukemia, 2003, 17(8), 1499-1507.
20. Vey, N.; Bosly, A.; Guerci, A.; Feremans, W.; Dombret, H.; Dreyfus, F.; Bowen, D.; Burnett, A.; Dennis, M.; Ribrag, V.; Casadevall, N.; Legros, L.; Fenaux, P. Arsenic trioxide in patients withmyelodysplastic syndromes: a phase II multicenter study. J. Clin.Oncol., 2006, 24(16), 2465-2471.
21. Schiller, G.J.; Slack, J.; Hainsworth, J.D.; Mason, J.; Saleh, M.; Rizzieri, D.; Douer, D.; List, A.F. Phase II multicenter study of arsenictrioxide in patients with myelodysplastic syndromes. J. Clin.Oncol., 2006, 24(16), 2456-2464.
22. Stone, R.M. Is intravenous arsenic trioxide a useful therapy inmyelodysplastic syndromes? J. Clin. Oncol., 2006, 24(16), 2414-2416.
23. Parmar, S.; Rundhaugen, L.M.; Boehlke, L.; Riley, M.; Nabhan, C.; Raji, A.; Frater, J.L.; Tallman, M.S. Phase II trial of arsenic trioxidein relapsed and refractory acute myeloid leukemia, secondaryleukemia and/or newly diagnosed patients at least 65 years old.Leuk. Res., 2004, 28(9), 909-919.
24. Lunghi, P.; Tabilio, A.; Dall'Aglio, P.P.; Ridolo, E.; Carlo-Stella, C.; Pelicci, P.G.; Bonati, A. Downmodulation of ERK activity inhibitsthe proliferation and induces the apoptosis of primary acutemyelogenous leukemia blasts. Leukemia, 2003, 17(9), 1783-1793.
25. Lunghi, P.; Costanzo, A.; Salvatore, L.; Noguera, N.; Mazzera, L.; Tabilio, A.; Lo-Coco, F.; Levrero, M.; Bonati, A. MEK1 inhibitionsensitizes primary acute myelogenous leukemia to arsenic trioxideinducedapoptosis. Blood, 2006, 107(11), 4549-53.
26. Takahashi, S.; Harigae, H.; Yokoyama, H.; Ishikawa, I.; Abe, S.; Imaizumi, M.; Sasaki, T.; Kaku, M. Synergistic effect of arsenictrioxide and flt3 inhibition on cells with flt3 internal tandem duplication.Int. J. Hematol., 2006, 84(3), 256-261.
27. Martelli, A.M.; Nyakern, M.; Tabellini, G.; Bortul, R.; Tazzari, P.L.; Evangelisti, C.; Cocco, L. Phosphoinositide 3-kinase/Akt signalingpathway and its therapeutical implications for human acutemyeloid leukemia. Leukemia, 2006, 20(6), 911-928.
28. Ramos, A.M.; Fernandez, C.; Amran, D.; Sancho, P.; de Blas, E.; Aller, P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptoticaction of the antileukemic drug arsenic trioxide via glutathionedepletion and increased peroxide accumulation in myeloidleukemia cells. Blood, 2005, 105(10), 4013-4020.
29. Szegezdi, E.; Cahill, S.; Meyer, M.; O'Dwyer, M.; Samali, A.TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br. J.Cancer, 2006, 94(3), 398-406.
30. Dai, J.; Weinberg, R.S.; Waxman, S.; Jing, Y. Malignant cells canbe sensitized to undergo growth inhibition and apoptosis by arsenictrioxide through modulation of the glutathione redox system.Blood, 1999, 93(1), 268-277.
31. Verma, A.; Mohindru, M.; Deb, D.K.; Sassano, A.; Kambhampati, S.; Ravandi, F.; Minucci, S.; Kalvakolanu, D.V.; Platanias, L.C.Activation of Rac1 and the p38 mitogen-activated protein kinasepathway in response to arsenic trioxide. J. Biol. Chem., 2002, 277(47), 44988-44995.
32. Goetz, M.P.; Toft, D.O.; Ames, M.M.; Erlichman, C. The Hsp90chaperone complex as a novel target for cancer therapy. Ann.Oncol., 2003, 14(8), 1169-1176.
33. Madrigal-Matute, J.; Lopez-Franco, O.; Blanco-Colio, L.M.; Munoz-Garcia, B.; Ramos-Mozo, P.; Ortega, L.; Egido, J.; Martin-Ventura, J.L. Heat shock protein 90 inhibitors attenuate inflammatoryresponses in atherosclerosis. Cardiovasc. Res., 2010, 86(2), 330-337.
34. Pelicano, H.; Carew, J.S.; McQueen, T.J.; Andreeff, M.; Plunkett, W.; Keating, M.J.; Huang, P. Targeting Hsp90 by 17-AAG in leukemiacells: mechanisms for synergistic and antagonistic drugcombinations with arsenic trioxide and Ara-C. Leukemia, 2006, 20(4), 610-619.
35. Guzman, M.L.; Neering, S.J.; Upchurch, D.; Grimes, B.; Howard, D.S.; Rizzieri, D.A.; Luger, S.M.; Jordan, C.T. Nuclear factorkappaBis constitutively activated in primitive human acute myelogenousleukemia cells. Blood, 2001, 98(8), 2301-2307.
36. Canestraro, M.; Galimberti, S.; Savli, H.; Palumbo, G.A.; Tibullo, D.; Nagy, B.; Guerrini, F.; Piaggi, S.; Cine, N.; Metelli, M.R.; Petrini, M. Synergistic antiproliferative effect of arsenic trioxidecombined with bortezomib in HL60 cell line and primary blastsfrom patients affected by myeloproliferative disorders. CancerGenet. Cytogenet., 2010, 199(2), 110-120.
37. Yan, H.; Wang, Y.C.; Li, D.; Wang, Y.; Liu, W.; Wu, Y.L.; Chen, G.Q. Arsenic trioxide and proteasome inhibitor bortezomib synergisticallyinduce apoptosis in leukemic cells: the role of proteinkinase Cdelta. Leukemia, 2007, 21(7), 1488-1495.
38. Bornhauser, B.C.; Bonapace, L.; Lindholm, D.; Martinez, R.; Cario, G.; Schrappe, M.; Niggli, F.K.; Schafer, B.W.; Bourquin, J.P. Low-dose arsenic trioxide sensitizes glucocorticoid-resistantacute lymphoblastic leukemia cells to dexamethasone via an Aktdependentpathway. Blood, 2007, 110(6), 2084-2091.
39. Redondo-Munoz, J.; Escobar-Diaz, E.; Hernandez Del Cerro, M.; Padiella, A.; Terol, M.J.; Garcia-Marco, J.A.; Garcia-Pardo, A. Inductionof B-chronic lymphocytic leukemia cell apoptosis by arsenictrioxide involves suppression of the PI3K/Akt pathway via JNK activation and PTEN upregulation. Clin. Cancer Res., 2010 Jun 9 [Epub ahead of print]
40. Zhang, W.; Ohnishi, K.; Shigeno, K.; Fujisawa, S.; Naito, K.; Nakamura, S.; Takeshita, K.; Takeshita, A.; Ohno, R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.Leukemia, 1998, 12(9), 1383-1391.
41. Bairey, O.; Vanichkin, A.; Shpilberg, O. Arsenic-trioxide-inducedapoptosis of chronic lymphocytic leukemia cells. Int. J. Lab Hematol., 2010, 32(1 Pt 1), e77-85.
42. Zhou, Y.; Hileman, E.O.; Plunkett, W.; Keating, M.J.; Huang, P. Free radical stress in chronic lymphocytic leukemia cells and itsrole in cellular sensitivity to ROS-generating anticancer agents.Blood, 2003, 101(10), 4098-4104.
43. Biswas, S.; Zhao, X.; Mone, A.P.; Mo, X.; Vargo, M.; Jarjoura, D.; Byrd, J.C.; Muthusamy, N. Arsenic trioxide and ascorbic aciddemonstrate promising activity against primary human CLL cells invitro. Leuk. Res., 2010, 34(7), 925-931.
44. Park, W.H.; Seol, J.G.; Kim, E.S.; Hyun, J.M.; Jung, C.W.; Lee, C.C.; Kim, B.K.; Lee, Y.Y. Arsenic trioxide-mediated growth inhibitionin MC/CAR myeloma cells via cell cycle arrest in associationwith induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res., 2000, 60(11), 3065-3071.
45. Liu, Q.; Hilsenbeck, S.; Gazitt, Y. Arsenic trioxide-induced apoptosisin myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy withAPO2/TRAIL. Blood, 2003, 101(10), 4078-4087.
46. Rousselot, P.; Larghero, J.; Labaume, S.; Poupon, J.; Chopin, M.; Dosquet, C.; Marolleau, J.P.; Janin, A.; Brouet, J.C.; Fermand, J.P.Arsenic trioxide is effective in the treatment of multiple myelomain SCID mice. Eur. J. Haematol., 2004, 72(3), 166-171.
47. Campbell, R.A.; Sanchez, E.; Steinberg, J.A.; Baritaki, S.; Gordon, M.; Wang, C.; Shalitin, D.; Chen, H.; Pang, S.; Bonavida, B.; Said, J.; Berenson, J.R. Antimyeloma effects of arsenic trioxide are enhancedby melphalan, bortezomib and ascorbic acid. Br. J. Haematol., 2007, 138(4), 467-478.
48. Grad, J.M.; Bahlis, N.J.; Reis, I.; Oshiro, M.M.; Dalton, W.S.; Boise, L.H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicityin multiple myeloma cells. Blood, 2001, 98(3), 805-813.
49. Abou-Jawde, R.M.; Reed, J.; Kelly, M.; Walker, E.; Andresen, S.; Baz, R.; Karam, M.A.; Hussein, M. Efficacy and safety results withthe combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med.Oncol., 2006, 23(2), 263-272.
50. Bahlis, N.J.; McCafferty-Grad, J.; Jordan-McMurry, I.; Neil, J.; Reis, I.; Kharfan-Dabaja, M.; Eckman, J.; Goodman, M.; Fernandez, H.F.; Boise, L.H.; Lee, K.P. Feasibility and correlates of arsenictrioxide combined with ascorbic acid-mediated depletion of intracellularglutathione for the treatment of relapsed/refractory multiplemyeloma. Clin. Cancer Res., 2002, 8(12), 3658-3668.
51. Lunghi, P.; Giuliani, N.; Mazzera, L.; Lombardi, G.; Ricca, M.; Corradi, A.; Cantoni, A.M.; Salvatore, L.; Riccioni, R.; Costanzo, A.; Testa, U.; Levrero, M.; Rizzoli, V.; Bonati, A. TargetingMEK/MAPK signal transduction module potentiates ATO-inducedapoptosis in multiple myeloma cells through multiple signalingpathways. Blood, 2008, 112(6), 2450-2462.
52. Wen, J.; Cheng, H.Y.; Feng, Y.; Rice, L.; Liu, S.; Mo, A.; Huang, J.; Zu, Y.; Ballon, D.J.; Chang, C.C. P38 MAPK inhibition enhancingATO-induced cytotoxicity against multiple myeloma cells. Br.J. Haematol., 2008, 140(2), 169-180.
53. Kapahi, P.; Takahashi, T.; Natoli, G.; Adams, S.R.; Chen, Y.; Tsien, R.Y.; Karin, M. Inhibition of NF-kappa B activation by arsenitethrough reaction with a critical cysteine in the activation loopof Ikappa B kinase. J. Biol. Chem., 2000, 275(46), 36062-36066.
54. Chauhan, D.; Hideshima, T.; Mitsiades, C.; Richardson, P.; Anderson, K.C. Proteasome inhibitor therapy in multiple myeloma. Mol.Cancer Ther., 2005, 4(4), 686-692.
55. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K.C. The proteasome inhibitorPS-341 inhibits growth, induces apoptosis, and overcomes drug resistancein human multiple myeloma cells. Cancer Res., 2001, 61(7), 3071-3076.
56. Wu, K.L.; Beksac, M.; van Droogenbroeck, J.; Amadori, S.; Zweegman, S.; Sonneveld, P. Phase II multicenter study of arsenictrioxide, ascorbic acid and dexamethasone in patients with relapsedor refractory multiple myeloma. Haematologica, 2006, 91(12), 1722-1723.
57. Borad, M.J.; Swift, R.; Berenson, J.R. Efficacy of melphalan, arsenictrioxide, and ascorbic acid combination therapy (MAC) in relapsedand refractory multiple myeloma. Leukemia, 2005, 19(1), 154-156.
58. Berenson, J.R.; Boccia, R.; Siegel, D.; Bozdech, M.; Bessudo, A.; Stadtmauer, E.; Talisman Pomeroy, J.; Steis, R.; Flam, M.; Lutzky, J.; Jilani, S.; Volk, J.; Wong, S.F.; Moss, R.; Patel, R.; Ferretti, D.; Russell, K.; Louie, R.; Yeh, H.S.; Swift, R.A. Efficacy and safetyof melphalan, arsenic trioxide and ascorbic acid combination therapyin patients with relapsed or refractory multiple myeloma: aprospective, multicentre, phase II, single-arm study. Br. J. Haematol., 2006, 135(2), 174-183.
59. Berenson, J.R.; Matous, J.; Swift, R.A.; Mapes, R.; Morrison, B.; Yeh, H.S. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatmentof relapsed or refractory multiple myeloma. Clin. Cancer Res., 2007, 13(6), 1762-1768.
60. Porosnicu, M.; Nimmanapalli, R.; Nguyen, D.; Worthington, E.; Perkins, C.; Bhalla, K.N. Co-treatment with As2O3 enhances selectivecytotoxic effects of STI-571 against Brc-Abl-positive acuteleukemia cells. Leukemia, 2001, 15(5), 772-778.
61. La Rosee, P.; Johnson, K.; Corbin, A.S.; Stoffregen, E.P.; Moseson, E.M.; Willis, S.; Mauro, M.M.; Melo, J.V.; Deininger, M.W.; Druker, B.J. In vitro efficacy of combined treatment dependson the underlying mechanism of resistance in imatinibresistantBcr-Abl-positive cell lines. Blood, 2004, 103(1), 208-215.
62. Amarante-Mendes, G.P.; Naekyung Kim, C.; Liu, L.; Huang, Y.; Perkins, C.L.; Green, D.R.; Bhalla, K. Bcr-Abl exerts its antiapoptoticeffect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.Blood, 1998, 91(5), 1700-1705.
63. Nimmanapalli, R.; Bali, P.; O'Bryan, E.; Fuino, L.; Guo, F.; Wu, J.; Houghton, P.; Bhalla, K. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res., 2003, 63(22), 7950-7958.
64. Konig, H.; Hartel, N.; Schultheis, B.; Schatz, M.; Lorentz, C.; Melo, J.V.; Hehlmann, R.; Hochhaus, A.; La Rosee, P. EnhancedBcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox)through glutathione-depletion in imatinib-resistant cells.Haematologica, 2007, 92(6), 838-841.
65. Du, Y.; Wang, K.; Fang, H.; Li, J.; Xiao, D.; Zheng, P.; Chen, Y.; Fan, H.; Pan, X.; Zhao, C.; Zhang, Q.; Imbeaud, S.; Graudens, E.; Eveno, E.; Auffray, C.; Chen, S.; Chen, Z.; Zhang, J. Coordinationof intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosisby imatinib mesylate combined with arsenic trioxide in chronicmyeloid leukemia. Blood, 2006, 107(4), 1582-1590.
66. Shah, N.P.; Nicoll, J.M.; Nagar, B.; Gorre, M.E.; Paquette, R.L.; Kuriyan, J.; Sawyers, C.L. Multiple BCR-ABL kinase domain mutationsconfer polyclonal resistance to the tyrosine kinase inhibitorimatinib (STI571) in chronic phase and blast crisis chronic myeloidleukemia. Cancer Cell, 2002, 2(2), 117-125.
67. Schiffer, C.A. BCR-ABL tyrosine kinase inhibitors for chronicmyelogenous leukemia. N. Engl. J. Med., 2007, 357(3), 258-265.
68. Wolf, G.; Smas, C.M. Retinoic acid induces the degradation of theleukemogenic protein encoded by the promyelocytic leukemia genefused to the retinoic acid receptor alpha gene. Nutr. Rev., 2000, 58(7), 211-214.
69. Zhang, X.W.; Yan, X.J.; Zhou, Z.R.; Yang, F.F.; Wu, Z.Y.; Sun, H.B.; Liang, W.X.; Song, A.X.; Lallemand-Breitenbach, V.; Jeanne, M.; Zhang, Q.Y.; Yang, H.Y.; Huang, Q.H.; Zhou, G.B.; Tong, J.H.; Zhang, Y.; Wu, J.H.; Hu, H.Y.; de The, H.; Chen, S.J.; Chen, Z. Arsenic trioxide controls the fate of the PML-RARalphaoncoprotein by directly binding PML. Science, 2010, 328(5975), 240-243.